4Fischer TA . et al . current status of phosphodiesterase inhibitors in the treatment of congestive heart failure[J] . Drugs , 1992; 44:928.
5Parker M ,et al . for the PROMISE study Research Group . Effect of oralmilinone on mortality in severe chronic heart failure[J]. New Engl J . Med . 1991,325: 1468.
6Heidenreich PA,Lee TT,Massie BM.Effect of beta-blockade on mortality in patients with heart failure:a meta-analysis of randomized clinical trials[J].J Am Coll Cardiol,1997,30(1):27-34
7Orime Y, Shiono M, Hata H, et al. Effects of phosphodiesteras inhibitors after coronary artery bypass grafting [J]. Jpn Circ J, 1999, 63(2) : 117- 122.
8Mollnoff T, Loick HM,Van Aken H, et al. Milrinone modulates endotoxemia systemic inflammation and subsequent acute phase response after cardiopulmonary bypass (CPB) [ J ]. Anesthesiology , 1999, 90(1): 72-80.
9Cusick DA, Pfeifer PB, Quigg RJ. Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure [J]. Am J cardiol, 1998, 82 (9): 1060- 1065.
1ARBEUS M,AXELSSON B,FRIBERG O,et al.Milrinone increases flow in coronary artery bypass grafts after cardiopulmonary bypass:a prospective,randomized,double-blind,placebo-controlled study[J].J Cardiothorac Vasc Anesth,2009,23(1):48-53.
2JEBELI M,GHAZINOOR M,MANDEGAR M H,et al.Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft:A randomized controlled trial[J].Cardiol J,2010,17(1):73-78.
3TOSAKA S,MAKITA T,TOSAKA R,et al.Cardioprotection induced by olprinone,a phosphodiesterase III inhibitor,involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion[J].J Anesth,2007,21(2):176-180.
4WANG H,GONG M,ZHOU B,et al.Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery[J].Adv Ther,2009,26(4):462-468.
5HIRABAYASHI Y,IGARASHI T,SAITOH K,et al.Comparison of the effects of amrinone,milrinone and olprinone in reversing bupivacaine-induced cardiovascular depression[J].Acta Anaesthesiol Scand,2000,44(9):1128-1133.
6ADACHI H,KAKIKI M,KISHI Y.Effects of a phosphodiesterase 3 inhibitor,olprinone,on rhythmical change in tension of human gastroepiploic artery[J].Eur J Pharmacol,2005,528(1-3):137-143.
7SKIMURA S, YOSHINO J, IZUMI K, et al. Comparison of the effects of phosphodiesterase III inhibitors, milrinone and olpri- none, in infant corrective cardiac surgery[ J]. Masuiy,2013,62 (5) :583 -588.
8MOKRA D, TONHAJZEROVA I, PISTEKOVA H, et al. Short- term cardiovascular effects of selective phosphodiesterase 3 inhibi- tor olprinone versus non-selective phosphodiesterase inhibitor aminophylline in ameconium-induced acute lung injury [ J ]. J Physiol Pharmacol, 2013,64 ( 6 ) : 751 - 759.
9WANG H, ZHANG B,SUN X, et al. Method development and validation of olprinone in human plasma by HPLC coupled with ESI-MS-MS: application to a pharmaeokinetic study[ J3. J Chro- matogr Sci ,2012,52 (5) :400 - 405.
10MASANOBU M, SHINICHI N, AKIRA A. Pharmacokinetics and pharmacodynamics of olprinone after cardiac surgery[ J]. O- saka City Meal,2004,50 ( 1 ) : 1 - 8.
